CFG
NVAX icon

Citizens Financial Group’s Novavax NVAX Stock Holding History

Citizens Financial Group’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-50
Closed -$2K – 665
2016
Q3 		$2K Buy
+50
New +$6.46K ﹤0.01% 618

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
QIM
Quantitative Investment Management Charlottesville, Virginia $963M AUM 12.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citizens Financial Group's NVAX Position: Q4 2016 in Review

Citizens Financial Group sold out of Novavax (NVAX) in Q4 2016, closing a stake of 50 shares — an estimated $2K sold.

Citizens Financial Group first reported a position in NVAX in Q3 2016 and held it in 1 quarter. The position peaked at $2K in Q3 2016. 142 funds tracked by Wall St. Rank hold NVAX as of Q4 2016.

  • Citizens Financial Group reported no remaining Novavax position as of Q4 2016 after selling out during the quarter.
  • Citizens Financial Group sold 50 Novavax shares in Q4 2016, an estimated $2K.
  • Citizens Financial Group first reported a position in Novavax in Q3 2016 and held it in 1 quarter.
  • Citizens Financial Group's Novavax position peaked at $2K in Q3 2016.
  • 142 funds tracked by Wall St. Rank held Novavax as of Q4 2016.

Based on Citizens Financial Group's 13F filing for Q4 2016, filed 10 Feb 2017.